All In MedTech

Device Trial Radar · NCT01851252

MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy

Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy

Last checked: Nov 20, 2026Latest source record: Dec 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Oct 2013

Primary completion

Aug 2017

Study completion Aug 2017

Sponsor

Lead sponsor
Meridian Bioscience, Inc.Not on our public-company list
Sponsor type
Industry
First posted
May 10, 2013

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Supportive care
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the effect on the (carbon 13 labelled(13C)-Methacetin Breath Test (MBT) of i.v. propranolol, a non-selective beta blocker (NSBB) following initial administration and after chronic use of each of these agents. The correlation of the MBT with Hepatic Venous Pressure Gradient (HVPG) measurement before and after treatment will be assessed. Additionally, the MBT measurements following 60 days of therapy will be compared to the first MBT measurement and to the second MBT measurement, post HVPG. Each patient's subsequent MBT measurement will be compared to his previous MBT results in order to determine his/her response to therapy.

Conditions

  • Chronic Liver Disease
  • Cirrhosis
  • Esophageal Varices
  • Portal Hypertension
  • Bleeding

Interventions

  • Methacetin (with Breath testing device)Device

    The methacetin is enriched with carbon 13, a stable non- radioactive isotope, and has been found to be safe in hundreds of studies. The material is very similar to acetominophen. 75 milligrams (mm) of this material pre- dissolved in water are used. This material undergoes rapid metabolism by the liver.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Correlation between HVPG and MBT and their changes following the i.v. administration of PropranololTime frame: 7 days
  2. The changes between MBT at baseline level and after chronic treatment in PropranololTime frame: 7 days
  3. MBT correlation to clinical events after 2 month of treatmentTime frame: 67 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Carmel Medical Center

    Haifa, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.